Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

Journal:

Nature Communications

Published:

2026-05-04

DOI:

10.1038/s41467-026-72544-z

Affiliations:

10

Authors:

21

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	10.250000 10.250000	0.49
Brigham and Women's Hospital (BWH), United States of America (USA)	6.000000	0.29
Harvard Medical School (HMS), United States of America (USA)	2.500000	0.12
Boston Children's Hospital (BCH), United States of America (USA)	2.000000	0.10
Broad Institute of MIT and Harvard, United States of America (USA)	0.250000	0.01

Interested in Oncology and Carcinogenesis?